Fludarabine induced autoimmune haemolytic anaemia in a patient with chronic lymphocytic leukaemia by Syed, Naveen Naz & Khurshid, Mohammad
eCommons@AKU
Department of Pathology and Laboratory Medicine Medical College, Pakistan
January 2006
Fludarabine induced autoimmune haemolytic





Aga Khan University, mohammad.khurshid@aku.edu
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Pathology Commons
Recommended Citation
Syed, N., Khurshid, M. (2006). Fludarabine induced autoimmune haemolytic anaemia in a patient with chronic lymphocytic
leukaemia. Journal of Pakistan Medical Association, 56(1), 44-45.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/552
Case Report
Fludarabine Induced Autoimmune Haemolytic Anaemia in a Patient with Chronic
Lymphocytic Leukaemia
Naveen Naz Syed, Mohammad Khurshid
Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi.
Abstract
Autoimmune haemolytic anaemia following fludara-
bine is an uncommon complication and previously treated
patients are at higher risk. 
We describe a case of 57- year old lady with chronic
lymphocytic leukaemia; she received intermittent courses of
alkylating agents and purine analogue, fludarabine.
Reintroduction of fludarabine for her relapsing disease
induced autoimmune haemolytic anaemia.
Numbers of cases have been reported regarding
autoimmune haemolytic anaemia following fludarabine
administration, but none have been published from our part
of the world.
Normally T-cell suppresses autoreactive lympho-
cytes that can produce autoantibodies. Suppression of T-
cells by fludarabine, in addition to the underlying disease
process appears to be a contributory factor for autoimmune
haemolytic anaemia.
Introduction
Autoimmune haemolytic anaemia (AIHA) is caused
by autoantibodies against antigens on the surface of red
blood cells.1 The result in increased destruction and short-
ened life span of erythrocytes.1
Autoimmune phenomenon is a well known compli-
cation of lymphoproliferative disorders, particularly of
chronic lymphocytic leukaemia (CLL).2
Fludarabine, a purine analogue was introduced as a
new and potent therapy for chronic lymphocytic leukaemia
in 19803 and since then, it is an effective and frequently
used agent for refractory and relapsing disease.4
Autoimmune disease, immunosuppression5 and second neo-
plasm in patients affected by B-cell chronic lymphoprolifer-
ative disorder are well known complications after fludara-
bine therapy.6
Autoimmune haemolytic anaemia is a rare complica-
tion of fludarabine therapy. Not many cases have been
reported in the literature, and none from Pakistan. 
We report a case of autoimmune haemolytic anaemia
following fludarabine in a patient with chronic lymphocytic
lymphoma.
Case Report
A 57 year old female presented in July 1999, with
complaints of fever and abdominal distension. General
physical and systemic examination revealed
hepatosplenomegaly. Complete blood counts showed:
white cell count 102x109/L with 88% lymphocytes, haemo-
globin 8.9g/dl and platelets 106x109/L. Bone marrow aspi-
rate and trephine biopsy revealed diagnosis of chronic lym-
phocytic leukaemia. She had Ann Arbor stage IV disease
and underwent splenectomy. Subsequently she was given
six intermittent courses of chlorambucil to control her pro-
gressive disease. After that she remained well for about
eight months.
Disease progression was seen again in December
2001, when her white blood cell count had risen to
99x109/L. Patient was otherwise well with normal haemo-
globin and platelets. Fludarabine monophosphate therapy
was initiated at dose of 40mg/m2 for five days, repeated
every four weeks. She received a total of nine courses over
a period of one year and showed a reasonably good
response.
Off therapy she remained well till January 2005,
when she presented with progressively rising white cells
count. Fludarabine was reintroduced at previous dose;
40mg/m2 for five days. At beginning of therapy complete
blood counts were: white cell count 105x109/L with 85%
lymphocyte, haemoglobin 10.2gm/dl and platelets
51x109/L and direct coombs test was negative. Two weeks
later, she presented with generalized weakness, shortness of
breath on minimal exertion and pallor. On physical exami-
nation, she had pallor, scleral icterus and tachycardia.
Complete blood counts at that time revealed: haemoglobin
4.8gm/dl, Hct 12.6%, TLC 4.5x109/L, platelet 41x109/L,
peripheral blood smear revealed spherocytes and nucleated
red blood cells (Figure). Other laboratory workup was
notable for reticulocyte count 26%, LDH 1064 IU/L, and
indirect bilirubin 4.5mg/dl (0.6-1.5mg/dl). Direct coombs
test was strongly positive with polyspecific anti IgG and
anti-C3d.
The patient was started on oral prednisolone
1mg/kg/day and meanwhile transfused with least incompat-
ible blood products. She showed marked and rapid 
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improvement with resolution of her symptoms and increase
in haemoglobin to 8.3gm/dl, Hct 24% and platelet 67,000/ul
after a week. Direct coombs test became negative and retic-
ulocyte count dropped to 11%. Prednisolone was gradually
tapered off over two months. On recent follow-up on 13
June 2005, complete blood count revealed Hb 13.0g/dl, Hct
38%, TLC 5.6x109/L and platelets 291x109/L.
Discussion
Chronic lymphocytic leukaemia is a low grade B-
cell lymphoproliferative disorder.6 Splenectomy, splenic
irradiation and alkylating agents are active therapies for the
disease but recurrence is frequently observed.6 During late
1980s, fludarabine emerged as a major drug in chronic lym-
phocytic leukaemia and generated tremendous interest.7
The incidence of autoimmune cytopenias in chronic
lymphocytic leukaemia is significantly higher than in gen-
eral population; autoimmune haemolytic anaemia, idiopath-
ic thrombocytopenic purpura and pure red cell aplasia occur
with incidence of 4-40%, 1-2% and less than 1% respective-
ly.1-3, 5, 8
It is reported that patients with de-novo CLL treated
for first time with fludarabine are unlikely to develop
autoimmune haemolytic anemia.8 Accumulated experiences
of several centers suggested that the incidence of fludara-
bine induced AIHA in patients with CLL with or without
positive DAT; ranges from 2% in previously untreated
patients to more than 20% in heavily pretreated patients.8
In addition, it was observed that patients, who have
been treated with multiple courses of alkylating agents, are
at higher risk of developing AIHA following fludarabine
therapy.9
Our patient was treated previously with alkylating
agents multiple times followed by fludarabine. Re-exposure
to fludarabine induced autoimmune haemolytic anaemia.
Although the etiology of autoimmune disease fol-
lowing purine analogue is unknown, but it appears to be
multifactorial.10
The most notable side effect of fludarabine is pro-
found and long lasting T-cell lymphocytopenia and alter-
ation of CD4-CD8 cell ratio10, these leads to loss of control
of normal T-cells to autoreactive lymphocytes. 
Raymond et al10 described that imbalance in the
CD4-CD8 ratio, is the best explanation for the development
of AIHA in patients who responded to fludarabine therapy
and this might be the reason in our patient as well. 
As our patient is an elderly lady, declining thymic
functions with advancing age and decreased T-cell function
in CLL may also act as contributory factors. 
So autoimmune haemolytic anaemia may have been
due to fludarabine associated immunosuppression, underly-
ing disease process, advancing age or combination of all.7
In summary, patient with chronic lymphocytic
leukaemia are more prone to develop autoimmune
haemolytic anaemia, especially when they are previously
heavily treated. So haematologic vigilance and a high index
of suspicion is essential throughout the period of fludara-
bine therapy especially in previously treated patients,
because haemolysis can occur without warning and requires
corticosteroid therapy promptly, which is the most effective
therapy for autoimmune haemolytic anaemia.
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